



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/632,187	07/30/2003	Jurgen Engel	103832-477-NP	9817

24964 7590 09/03/2010  
GOODWIN PROCTER LLP  
ATTN: PATENT ADMINISTRATOR  
620 Eighth Avenue  
NEW YORK, NY 10018

EXAMINER
----------

GEMBEH, SHIRLEY V

ART UNIT	PAPER NUMBER
----------	--------------

1628

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

09/03/2010

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

bdowd@goodwinprocter.com  
patentny@goodwinprocter.com

<b>Office Action Summary</b>	<b>Application No.</b> 10/632,187	<b>Applicant(s)</b> ENGEL ET AL.	
	<b>Examiner</b> SHIRLEY V. GEMBEH	<b>Art Unit</b> 1628	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 10 May 2010.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,3,4 and 12 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3,4 and 12 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |                                                                                        |                                                                   |
|----------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                       | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>2/10/10</u> .                                                 | 6) <input type="checkbox"/> Other: _____                          |

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/10/10 has been entered.
2. Applicant's arguments filed 5/10/10 have been fully considered but they are not deemed to be persuasive.
3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
4. Claims 1, 3-4 and 12 are pending in this office action.
5. The information disclosure statement (IDS) submitted on 5/10/10 is acknowledged and has been reviewed.

Art Unit: 1628

6. The rejection of claims 1 and 3 under 35 U.S.C. 103(a) as being unpatentable over Hilgard et al. (1993) and Calabresi in view of Goodman and Gilman is withdrawn because Hilgard et al. fails to teach the claimed compound of formula II as recited.

***Claim Rejections - 35 USC § 112***

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1 and 3-4 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

No proper antecedent basis or conception in context with that described in the specification at the time of filing the instant application is apparent for the recitation of "antimetabolite" thereby constituting new matter. Applicant is invited to indicate by page and line number where such a limitation is described.

**Affidavit**

8. The affidavit under 37 CFR 1.132 filed 5/10/10 is insufficient to overcome the rejection of claims 1, 3-4 and 12 based upon the rejection over Nickel et al. (US Patent

6,696,428) and Hilgard et al. (1993) in view of Stekar et al. (1995) and Goodman and Gilman (all made of record) because:

Ex parte Gelles 22 USPQ 2d 1318 (at 1319): held that "[t]he evidence relied upon also should be reasonably commensurate in scope with the subject matter claimed and illustrate the claimed subject matter "as a class" relative to the prior art subject matter." Also in order to show unexpected results three major points that should be considered: the unexpected result must truly be unexpected, it must be commensurate in scope (show a trend representing the scope), and lastly a direct comparison with the closest prior art of record should be provided.

Declarant has not provided evidence that a trend exists that the many substituents of compound of formula II would give the same unexpected result, and therefore is not commensurate in scope with that claimed. The only compound with the unexpected result is perifosin which by itself is insufficient to overcome the rejection of record.

### ***Claim Rejections - 35 USC § 103***

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 3-4 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nickel et al. (US Patent 6,696,428) and Hilgard et al. (1993) in view of Stekar et al. (1995) and Goodman and Gilman (all previously made of record).

Nickel et al. teach anti-tumor compounds such as miltefosine or octadecyl (1,1-dimethylpiperidinio-4-yl) phosphate (i.e., perifosine), wherein said compounds are used in pharmaceutical compositions or dose units (i.e. drug products) for effective treatment of cancer (see col. 1, lines 10-17; col. 2, lines 40-44; claims 1 and 12).

However Nickel fails to teach treating mammary cancer and also fails to teach that the treatment requires an antimetabolite (such as 5-fluorouracil, fludarabin, gemcitabin and cytarabin).

Hilgard teach an analog of perifosine (i.e., miltefosin, an alkyphosphocholine compound) for the treatment of mammary carcinoma (see pg 91 under activity of miltefosine) in combination with cisplatin (see pg 93).

However Hilgard fails to teach the structural compound of formula II of instant claim 1 and the specific antimetabolites recited.

Stekar et al. teach the drug miltefosine is administered before or prior to the administration of cyclophosphamide (see page 373, rt. col. as in claims 4 and 12).

However Skekar fails to teach the use the octadecyl (1,1- dimethylpiperidinio-4-yl) phosphate (i.e., perifosine) as required by instant claim 1 and 12 compound formula II.

One of ordinary skill in the art would have been motivated to expand the generic treatment method of cancers as taught by Nickel to include treating mammalian cancers as taught by Hilgard, and to substitute Hilgard's drug miltefosin for perifosin with a reasonable expectation of success because both drugs are functionally equivalent as taught by Nickel.

Goodman et al. disclose in Table X-1 a list of known anti-tumor agents, such as 5-fluorouracil or cyclophosphamide etc., for treating cancers or tumors.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to further modify the methods of both Nickel et al. by additionally

Art Unit: 1628

administering the anti-tumor agents disclosed by Calabresi/Goodman et al. because one of ordinary skill in the art would reasonably expect the combined properties of the anti-tumor compounds to effectively treat patients suffering from tumors or cancer.

Moreover, Calabresi/Goodman et al. teach that drugs are generally more effective in combination therapy and may be synergistic through biochemical interactions.

Thus, the claimed invention was prima facie obvious to at the time of filing.

### ***Double Patenting***

10. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims **1, 3-4 and 12** are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims **1-19** of U.S. Patent Application No. **12751608**. Although the conflicting claims are not identical, they are not patentably distinct from each other. The reasons are as follows:



- • The claims of the instant application '187 refer to treating mammalian cancer comprising administration of an alkylphosphocholine of compound of formula II with an antimetabolite (see claim 1 and 12) and the copending application '608 refers to use of a formulation of an alkylphosphocholine in combination of an antimetabolite for the treatment of cancer (see claim 1).
- • Both applications recite using the same compositions and/or derivatives thereof. See current application claims 1, 3-4 and 12 and copending application claims 1-19. The compositions recited in the claims are anticipatory of each other.

In view of the foregoing, the copending application claims and the current application claims are obvious variations.

11. Claims **1, 3-4 and 12** are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims **1-14** of U.S. Patent Application No. **12751454**. Although the conflicting claims are not identical, they are not patentably distinct from each other. The reasons are as follows:

- • The claims of the instant application '187 refer to treating mammalian cancer comprising administration of an alkylphosphocholine of compound of formula II with an antimetabolite (see claim 1) and the copending application '454 refers to a treating oncogenesis/cancers generically with a formulation of

an alkylphosphocholine in combination of an antimetabolite for the treatment of cancer (see claim 1).

- • Both applications recite using the same compositions and/or derivatives thereof. See current application claims 1, 3-4 and 12 and copending application claims 1-14. The compositions recited in the claims are anticipatory of each other.
- One of ordinary skill in the art would have been motivated to use the generic treatment of cancers recited by the copending application to treat specific cancers such as mammalian cancers recited in the instant application with a reasonable expectation of success.

In view of the foregoing, the copending application claims and the current application claims are obvious variations.

12. No claim is allowed.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHIRLEY V. GEMBEH whose telephone number is (571)272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brandon Fetterolf can be reached on 571-272-2919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1628

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/S. V. G./  
Examiner, Art Unit 1628  
8/20/2010

/Robert C. Hayes/  
Primary Examiner, Art Unit 1649